Study Details
Study of ASP0739 Alone and with Pembrolizumab in Advanced Solid Tumors with NY-ESO-1 Expression Participants
Clinicaltrials.gov ID
Astellas Study ID
0739-CL-0101
EudraCT ID
N/A
Condition
Ovarian Cancer, Non Small Cell Lung Cancer, Stomach or Esophageal Cancer, Advanced/Metastatic Cancer
Phase
Phase 1
Age
18 Years - N/A
Sex
Female & Male
Product
ASP0739
Type
Interventional
Trial Dates
Jan 2022 - May 2023
Masking
None (Open Label)
Enrollment number
16
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors known to Express NY-ESO-1
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Study of ASP0739 Alone and with Pembrolizumab in Advanced Solid Tumors with NY-ESO-1 Expression Participants? Contact us by filling our your information to the right and we’ll respond to you.
Locations
City of Hope
Duarte, United States, 91010
Northwestern University Robert H. Lurie Comprehensive Cancer Center
Chicago, United States, 60611
University of Miami
Miami, United States, 33136
Brown University
Providence, United States, 02903
The University of Chicago Medicine
Chicago, United States, 60637
Oregon Health & Science University
Portland, United States, 97239
NYU Perlmutter Cancer Center
New York, United States, 10016